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Objective: Transmyocardial laser revascularization is a new technique that improves
symptoms in patients with refractory angina not amenable to conventional revas-
cularization. The aim of this study was to assess whether transmyocardial laser
revascularization produces changes in innervation, perfusion scintigraphy, or both
that could explain the benefit to patients.
Methods: Sixteen patients (12 men and 4 women; mean age, 60  8 years) with
coronary artery disease were studied. Transmyocardial laser revascularization was
performed in 39 myocardial areas supplied by a stenotic vessel. A technetium
99m-labeled tetrofosmin stress-rest tomographic scan and iodine 123-labeled meta-
iodobenzylguanidine planar scans were performed before and after transmyocardial
laser revascularization (3 and 12 months later) to evaluate myocardial perfusion and
innervation. Stress and rest perfusion images were quantified on a polar map.
Ischemia uptake was also defined as the difference between rest and stress uptake
for each area. Innervation planar images were visually analyzed and semiquantified.
Results: A significant decrease in angina class from baseline was observed at 3, 6, and
12 months after transmyocardial laser revascularization (P  .005). A significant
decrease in ischemia uptake was also found between the pre-transmyocardial laser
revascularization and the post-transmyocardial laser revascularization studies in treated
areas (P .001). A significant improvement in stress myocardial perfusion at 3 and 12
months after transmyocardial laser revascularization was only found in treated areas that
were considered ischemic in the pre-transmyocardial laser revascularization study (P
.05). At 3 months, a significant myocardial innervation worsening was observed in
treated areas (P  .001), with partial recovery at 12 months (P  .05).
Conclusion: The transmyocardial laser revascularization mechanism involves both
perfusion improvement and denervation, mainly at 3 months, that partially recov-
ered at 12 months.
Transmyocardial laser revascularization (TMR) is a new technique forthe treatment of refractory angina not amenable to either percutane-ous angioplasty or bypass surgery.1 Two different types of lasersystems have been described, the CO2 laser and the holmium-YAGlaser. Clinical trials have demonstrated that both of these laserssignificantly improve angina in those patients who are not candidates
for conventional therapies.2 However, the mechanism of TMR action is still poorly
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understood. Its beneficial action on anginal class has been
attributed to an improvement in regional blood flow through
the newly created channels or to the stimulation of a neo-
angiogenesis process, but significant differences in myocar-
dial perfusion have been demonstrated in only a few pub-
lications.2 Another mechanism for angina relief could be
sympathetic denervation, which might improve angina
without influencing myocardial perfusion in the early post-
operative period, as has been observed in one positron
emission tomography study.3
The aim of this study was to clarify the mechanism of
action of TMR on anginal symptoms by testing the 2 hy-
potheses during the first year after TMR by using conven-
tional nuclear medicine procedures. Therefore a prospective
study was conducted to determine whether TMR with a
holmium-YAG laser produces differences in myocardial
perfusion, myocardial sympathetic innervation, or both, 3 or
12 months after revascularization and whether there is any
possible relationship to the changes in functional class.
Materials and Methods
Patients
This study included 16 consecutive patients (12 men and 4 women;
mean age, 60  8 years) who underwent TMR as a part of a
prospective study that was approved by the hospital ethics com-
mittee. All of the patients had coronary artery disease, had a
preoperative Canadian Cardiovascular Society Score (CCSS) for
angina of III or IV, and were not candidates for conventional
coronary interventions. Six patients had type II diabetes mellitus,
12 had hypercholesterolemia, and 8 had hypertension. Eleven
patients had a past history of coronary artery bypass grafting or
percutaneous transluminal coronary angioplasty. None had recent
myocardial infarction. Two patients had single-vessel disease, and
14 patients had multivessel disease (ie, 2 vessels in 3 patients and
3 vessels in 11 patients). Mean preoperative left ventricular ejec-
tion fraction was 57% (57%  13%; range, 28%-77%). Informed
consent was obtained from each patient enrolled.
Surgical Procedure
TMR was performed in 39 myocardial areas, defined as apical,
anterior, lateral, or inferior, as is usually the case in perfusion
tomographic studies. All treated areas were supplied by significant
(70%) stenotic vessels, as determined by means of coronary
arteriography. This criteria was also applied in innervation studies,
although only planar scans were obtained.
Cardiac exposure was accomplished through a limited left
anterior thoracotomy in the fifth intercostal space. A commercially
available, 20-W, pulsed holmium-YAG laser (Eclipse, Cardiogen-
esis, Soophell, Ranch, Calif) was used to create transmyocardial
channels. The laser was calibrated to deliver 6 to 8 W per pulse,
and energy was delivered at the rate of 5 pulses per second through
a flexible 1-mm optical fiber. Energy application was not gated to
the cardiac cycle or in syncrony with diastole. The epicardial holes
were performed every square centimeter throughout the apical two
thirds of the left ventricle. Hemostasis was achieved by means of
epicardial digital pressure, and the thoracotomy was closed in a
routine fashion. A mean of 2.44  0.89 areas were treated per
patient, and a mean of 14.3  3.2 channels were created per
myocardial area (mean, 34  14 channels; 10-43 channels per
patient). Patients were monitored in the intensive care unit imme-
diately after the operation. No bleeding complications were en-
countered in any patient.
Study Design
Anginal class was recorded at baseline and at 3, 6, and 12 months
after TMR by a blinded individual with the CCSS score for angina.
Technetium 99m-labeled tetrofosmin (99mTc-tetrofosmin) pharma-
cologic stress-rest single-photon emission computed tomography
(SPECT) and a iodine 123-labeled metaiodobenzylguanidine (123I-
MIBG) innervation scan (planar and SPECT) were also performed
at baseline and after TMR (3 and 12 months). Ten of the 39 areas
treated had to be excluded in the innervation tomographic analysis
because of a high level of extramyocardial activity. Because of
this, only innervation planar scans were analyzed.
Scintigraphic Studies
A standard dipyridamole protocol was used for the pharmacologic
stress testing. 99mTc-Tetrofosmin stress-rest imaging was per-
formed according to the stress-rest protocol in which 7 to 9 mCi
(260-333 MBq) of 99mTc-tetrofosmin are administered at stress,
with stress imaging obtained 60 minutes later. Three hours later,
21 to 25 mCi (777-925 MBq) of 99mTc-tetrofosmin were injected
at rest, obtaining rest imaging 60 minutes later. All images were
processed according to standard protocols. The coronal slices were
also generated to obtain a bull’s-eye (polar map) that was later
divided into different regions of interest (Figure 1). The 99mTc-
tetrofosmin uptake of the left ventricular myocardium at stress and
rest were measured quantitatively on the polar map by using an
automatic program. Ischemia uptake was also defined as the dif-
ference between rest and stress uptake for each region of interest.
The regions were matched with the myocardial treated areas, as
shown in Figure 1. All the studies were analyzed by using the same
protocol and criteria.
The innervation study was done between 4 and 20 days after
the perfusion SPECT. The thyroid gland was blocked with 20
Lugol drops.4 Three hours later, 8 to 10 mCi (296-370 MBq) of
Figure 1. Polar map divided into 9 regions of interest. 1 and 2,
Anterior area; 3 and 4, septal area; 5 and 6, inferior area; 7 and 8,
lateral area; 9, apical area.
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123I-MIBG, an analog of norepinephrine, was injected. The study
was performed 4 hours after injection to allow for clearance of
nonspecific tissue uptake,5 and planar images (anterior and 45° and
70° left anterior oblique images) were acquired. Laser- and non-
laser-treated areas in the different studies were visually evaluated
by 3 experienced observers by means of consensus, as previously
reported, and semiquantified as absent uptake (0), severe defect
(1), moderate defect (2), mild defect (3), or normal area (4). The
observers had no knowledge of the clinical data, perfusion scans,
or coronary arteriography results.
Statistical Analysis
All measures recorded at baseline and follow-up were compared
by using the Wilcoxon signed-rank test. Results are expressed as
means  SD.
Results
Clinical Data
One patient died at 6 months of a noncardiac cause (pneu-
monia), one patient did not undergo the 12-month perfusion
study because of technical problems, and in another patient
the 3-month scintigraphy was not performed because of a
rib fracture. In the remaining patients the follow-up was
completed.
CCSSs for angina during follow-up are presented in
Figure 2, A. Considering the preoperative status, 14 of 16
patients improved their angina class at 3 months. In 11
patients improvement persisted at 6 and 12 months. In 5
patients there was an anginal class worsening between the
3rd and 12th months but without complete recovery to the
basal status. There were only 2 patients who did not change
anginal class during the first year. Overall, anginal class
improved significantly from the preoperative period (3.38
0.50) to 3 months (1.63  0.72, P  .001), 6 months
(1.80  0.86, P  .005), and 12 months (1.93  0.80, P 
.005) after TMR.
Perfusion Studies
Areas with normal uptake (85%) or absent uptake
(20%) in the pre-TMR study did not change after the
operation.
In laser-treated areas a significant decrease in ischemic
(rest-stress) myocardial uptake was found between the pre-
TMR study (8.00  6.45) and the 3-month (1.03  5.65,
P  .001) and 12-month (0.05  7.05, P  .001) post-
TMR studies (Figure 2, B, and 3).
No statistical differences were found in stress or rest
perfusion uptake between laser- and nonlaser-treated areas
during follow-up. However, in the subgroup of patients with
ischemic areas before TMR, a significant improvement was
also found at stress in treated areas (Figure 3) between the
pre-TMR study (68.56  15.77) and the 3-month (73.49 
14.15, P  .05) and 12-month (69.52  15.15, P  .05)
post-TMR studies (Figure 3).
Innervation Studies
Five areas were excluded from this evaluation because of a
high level of lung or liver activity (n  3). Areas without
uptake did not change during follow-up (8/34). Of the 26
areas with basal uptake, innervation worsened at 3 months
in 15 and did not change in 10. The remaining area corre-
sponded to a patient not undergoing the 3-month studies.
Nine of the worsened areas had improved innervation at 12
months (Figure 2, C, and 4). Of the remaining 6 worsened
areas, 3 did not change, and 2 continued to worsen at 12
months, whereas one corresponded to a patient who died at
Figure 2. A, Evolution of anginal class in the different patients. B,
Evolution of ischemia uptake (rest-stress myocardial uptake) in
laser-treated areas. C, Evolution of myocardial innervation in
laser-treated areas. Data are shown for before the operation
(pre-TMR) and at 3 and 12 months after the operation (post-TMR).
Muxı´ et al Cardiopulmonary Support and Physiology
The Journal of Thoracic and Cardiovascular Surgery ● Volume 125, Number 6 1495
CS
P
6 months. Overall, a significant decrease in innervation
from baseline (2.50  1.58) was found in the laser-treated
areas at 3 months (1.94  1.56, P  .001) and 12 months
(2.29  1.53, P  .01). It is worth noting that a significant
innervation improvement was detected from 3 to 12 months
(P  .05). Finally, of the 9 normal preoperative innervation
areas, 6 did not change during follow-up.
Considering the results on a patient-per-patient basis, in
10 of the 15 patients who were studied at 3 months, there
was both angina improvement and denervation in at least
one of the laser-treated areas. Moreover, in 4 of the 5
patients whose anginal class worsened between the 3rd and
12th months, there was also a reinnervation in at least one
of the laser-treated areas.
Discussion
Evolution in Clinical Symptoms
TMR has been introduced as therapy for patients with
medically refractory angina and diffusely diseased vessels
that are not amenable to conventional revascularization
therapies.1,2,6 In almost all published TMR studies, perfu-
sion scintigraphic reversible ischemia is a main inclusion
criterion.7 In our study the main inclusion criterion was the
presence of severe refractory angina and diffuse coronary
artery disease determined by means of coronary arteriogra-
phy independently of the perfusion scan. In spite of this, a
significant improvement in angina class was documented at
3, 6, and 12 months with respect to the preoperative status.
Only 2 patients experienced no improvement in clinical
symptoms. In one of these patients with previous myocar-
dial infarction, the only treated area had less than 20%
perfusion uptake on the polar map and absent uptake in the
innervation study.
In our study angina class improved at 3 months after
TMR but tended to worsen later on without reaching the
preoperative status. In line with our results, different au-
thors8-10 found a trend toward worsening over time; in
contrast, patients studied by Frazier and colleagues11 had
improved angina status with time.
Perfusion Improvement
Improved anginal status has been thought to be secondary to
increased myocardial perfusion,12,13 either through patent
TMR myocardial channels or through a process of neoan-
giogenesis developing in the treated areas. Permeability of
laser channels is controversial. Although there is histologic
evidence of early occlusion of laser channels,14 inflamma-
tory cells recruited in response to laser-induced myocardial
injury might release angiogenic growth factors15 that might
result in neovascularization. This is a slow process begin-
ning 2 to 3 weeks after TMR, with a progressive increase
thereafter.13
Figure 3. 99mTc-Tetrofosmin stress-rest SPECTs. The patient was referred for right coronary artery disease. TMR
was performed on the inferior area. Before the operation, the stress tomography showed a moderate inferior defect
that improved at rest. Twelve months after the operation, the inferior territory had improved its perfusion at stress
and had decreased ischemic uptake (rest-stress) compared with basal study.
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Four different randomized studies comparing TMR with
medical treatment have been published.2,8,11,16 In all, 4
TMRs produced a significantly better clinical outcome, but
only one found an improvement in myocardial perfusion.11
This discrepancy could be due to a difference in patient
selection, scintigraphic methods, or surgical technique.17
In our study a significant decrease in ischemia uptake
was found in laser-treated areas between the pre-TMR and
post-TMR studies (3 and 12 months), as has been observed
in other published studies.7 When analyzing only laser-
treated areas that were considered ischemic before the op-
eration, a significant stress perfusion improvement was also
found between pre-TMR studies and the 3- and 12-month
post-TMR studies.
Denervation
The second mechanism thought to be involved in TMR is
denervation.3 Denervation might damage cardiac nerve fi-
bers18 that convey pain, improving angina without influenc-
ing myocardial perfusion. In our experience, as has been
reported by others,19 it is difficult to obtain adequate tomo-
graphic innervation scans because the reconstruction pro-
cess can vary widely from one trained observer to another,
especially in the most denervated myocardium. Therefore
only planar scans were considered in our study.
It is known that adrenergic function is more sensitive to
ischemia than the associated perfusion abnormality20 and
that repetitive episodes of ischemia can induce a permanent
loss of neuronal MIBG uptake in the myocardium.21 This
fact might explain the lack of correlation between perfusion
and innervation uptake.
There has been one positron emission tomography study
that demonstrates denervation induced by TMR in human
subjects without long-term follow-up,3 but myocardial de-
nervation has never been demonstrated in conventional
scintigraphic studies until now. In our study innervation was
worse in the visual analysis at 3 months than preoperatively
in 15 laser-treated areas (P  .005). At 12 months, 9 of
these 15 areas had improved (P  .05). As has been de-
scribed in the “Results” section, in 10 of the 15 patients who
were studied at 3 months, there was both angina improve-
ment and denervation in at least one of the laser-treated
areas. Moreover, in 4 of the 5 patients whose anginal class
worsened between the 3rd and 12th months, there was also
a reinnervation in at least one of the laser-treated areas.
Therefore these results would indicate that reinnervation
can take place in the long term (12 months), as found in
patients undergoing heart transplantation.22 This hypothesis
could explain why angina class in our patients seems to
worsen during follow-up.
Six normal preoperative areas did not change in terms of
innervation on visual analysis during the entire study. Al-
though the analysis was not sensitive enough to detect
minimal changes, it is possible that some differences in their
response could be related to variations in surgical technique
or patients’ differences.17 Therefore dose response could be
related to the number of channels made and might influence
evaluation of TMR efficacy.23
It must be underlined that denervation might have a
detrimental effect on the heart. Because laser energy ablates
myocardial tissue, there is concern that TMR might de-
crease angina by creating myocardial zones of necrosis.
However, neither differences in fixed perfusion defects2 nor
a significant difference in the rate of survival at 12 months
between the TMR and medically treated groups have been
demonstrated,2,11 and none of our patients had a myocardial
infarct or severe arrythmia during the follow-up period.
Figure 4. 123I-MIBG left anterior oblique 45° planar scans. The patient was referred for right coronary and left
circumflex artery disease. TMR was performed on the inferior and lateral areas. The planar scans showed an
inferolateral moderate defect before the operation, a severe defect at 3 months, and a partial recovery at 12 months.
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Study Limitations
First, the number of patients and the areas involved were
relatively small. However, this limitation is partially over-
come by the fact that each patient has been studied at 3
different time points. Second, MIBG uptake might be in-
fluenced by medication.24 Although this drug interaction
could be an important limitation, the study was designed as
a paired data trial, and patients were not advised to discon-
tinue therapy during the follow-up period. Also, the pres-
ence of diabetes might interfere with the biodistribution of
MIBG. We have found only 2 areas with worse innervation
at 12 months when compared with the 3-month study, and
both of these corresponded to a diabetic patient. Finally, a
third limitation might derive from the nonexact anatomic
matching between the treated areas and the scintigraphic
areas, especially when MIBG is used. In this regard, how-
ever, it is worth noting that perfusion quantification was
automatic and that MIBG planar image evaluation and final
correlation were made by 3 observers without knowledge of
the clinical data.
Conclusion
The mechanism of TMR action is probably multifactorial,
including both perfusion improvement and myocardial de-
nervation, mainly in the early postoperative period, in laser-
treated areas. Larger long-term studies are warranted to
confirm the possibility of reinnervation at 12 months after
TMR.
We thank nuclear medicine technicians, Blanca Ochoa and
Anna Puig, for their skillful help in the realization of these studies.
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